Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)

This study has been terminated.
(Due to declining numbers of patients with unsuppressed viremia, Gilead combined the studies GS-US-183-0144 and 0145 into one study (GS-US-183-0145).)
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT00707733
First received: June 27, 2008
Last updated: February 11, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2010
  Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: January 16, 2014